scholarly journals Positive Correlation Between the Efficiency of Induced Pluripotent Stem Cells and the Development Rate of Nuclear Transfer Embryos When the Same Porcine Embryonic Fibroblast Lines Are Used As Donor Cells

2014 ◽  
Vol 16 (3) ◽  
pp. 206-214 ◽  
Author(s):  
Bingteng Xie ◽  
Jianyu Wang ◽  
Shichao Liu ◽  
Jiaqiang Wang ◽  
Binghua Xue ◽  
...  
2015 ◽  
Vol 17 (1) ◽  
pp. 19-27 ◽  
Author(s):  
Sergio D. German ◽  
Keith H.S. Campbell ◽  
Elisabeth Thornton ◽  
Gerry McLachlan ◽  
Dylan Sweetman ◽  
...  

Cells ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 49
Author(s):  
Aisha Mohamed ◽  
Theresa Chow ◽  
Jennifer Whiteley ◽  
Amanda Fantin ◽  
Kersti Sorra ◽  
...  

The clinical application of induced pluripotent stem cells (iPSC) needs to balance the use of an autologous source that would be a perfect match for the patient against any safety or efficacy issues that might arise with using cells from an older patient or donor. Drs. Takahashi and Yamanaka and the Office of Cellular and Tissue-based Products (PMDA), Japan, have had concerns over the existence of accumulated DNA mutations in the cells of older donors and the possibility of long-term negative effects. To mitigate the risk, they have chosen to partner with the Umbilical Cord (UC) banks in Japan to source allogeneic-matched donor cells. Production of iPSCs from UC blood cells (UCB) has been successful; however, reprogramming blood cells requires cell enrichment with columns or flow cytometry and specialized growth media. These requirements add to the cost of production and increase the manipulation of the cells, which complicates the regulatory approval process. Alternatively, umbilical cord tissue mesenchymal stromal cells (CT-MSCs) have the same advantage as UCB cells of being a source of young donor cells. Crucially, CT-MSCs are easier and less expensive to harvest and grow compared to UCB cells. Here, we demonstrate that CT-MSCs can be easily isolated without expensive enzymatic treatment or columns and reprogramed well using episomal vectors, which allow for the removal of the reprogramming factors after a few passages. Together the data indicates that CT-MSCs are a viable source of donor cells for the production of clinical-grade, patient matched iPSCs.


Cell Research ◽  
2010 ◽  
Vol 20 (7) ◽  
pp. 850-853 ◽  
Author(s):  
Shuya Zhou ◽  
Chenhui Ding ◽  
Xiaoyang Zhao ◽  
Eryao Wang ◽  
Xiangpeng Dai ◽  
...  

2010 ◽  
Vol 19 (2) ◽  
pp. 239-246 ◽  
Author(s):  
Huseyin Sumer ◽  
Karen L. Jones ◽  
Jun Liu ◽  
Corey Heffernan ◽  
Pollyanna A. Tat ◽  
...  

Cell Research ◽  
2011 ◽  
Vol 21 (10) ◽  
pp. 1509-1512 ◽  
Author(s):  
Xiaoping Han ◽  
Jianyong Han ◽  
Fangrong Ding ◽  
Suying Cao ◽  
Seong Soo Lim ◽  
...  

2020 ◽  
Vol 66 (2) ◽  
pp. 163-174
Author(s):  
Seiki HARAGUCHI ◽  
Thanh Quang DANG-NGUYEN ◽  
David WELLS ◽  
Daiichiro FUCHIMOTO ◽  
Tomokazu FUKUDA ◽  
...  

2018 ◽  
Vol 115 (47) ◽  
pp. E11071-E11080 ◽  
Author(s):  
Dawei Yu ◽  
Jing Wang ◽  
Huiying Zou ◽  
Tao Feng ◽  
Lei Chen ◽  
...  

Substantial rates of fetal loss plague all in vitro procedures involving embryo manipulations, including human-assisted reproduction, and are especially problematic for mammalian cloning where over 90% of reconstructed nuclear transfer embryos are typically lost during pregnancy. However, the epigenetic mechanism of these pregnancy failures has not been well described. Here we performed methylome and transcriptome analyses of pig induced pluripotent stem cells and associated cloned embryos, and revealed that aberrant silencing of imprinted genes, in particular the retrotransposon-derived RTL1 gene, is the principal epigenetic cause of pregnancy failure. Remarkably, restoration of RTL1 expression in pig induced pluripotent stem cells rescued fetal loss. Furthermore, in other mammals, including humans, low RTL1 levels appear to be the main epigenetic cause of pregnancy failure.


Sign in / Sign up

Export Citation Format

Share Document